Navigation Links
Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Tuesday, September 13, 2011, at 2:25 p.m. Eastern Time.  The conference is being held September 11-13 at The Waldorf-Astoria in New York City.  An audio webcast of the Company's presentation will be available live and by replay and can be accessed at or the Investors section of Cardium's website at  The investor presentation slides are available and can be viewed at


About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium healthy lifestyle product platform.  The Company's lead product candidates include Excellagen™ topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at

Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Provides Update on Exchange Listing and Related Business Matters
2. Cardium to Present at Southern California Investor Conference
3. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
4. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
5. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
6. Cardium Reports on Transdel Transaction
7. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
8. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
9. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
10. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
11. Cardium to Present at OneMedForum San Francisco 2011 Conference
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):